Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sabcomeline SCHEMBL3133975 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3843721 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3133982 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL7076525 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL7079710 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6392265 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL34463221 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL18049048 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6629873 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6629868 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116877-A1 | New Salt Forms of Sabcomeline | Syremis Therapeutics, Ltd. (IL) | 2026-04-30 | — | — | US | claimed |
| US-20260116876-A1 | NEW SALT FORMS OF SABCOMELINE | Syremis Therapeutics, Ltd. (IL) | 2026-04-30 | — | — | US | claimed |
| US-20260102381-A1 | Muscarinic Agent Combinations | Syremis Therapeutics, Ltd. (IL) | 2026-04-16 | — | — | US | claimed |
| US-20260103460-A1 | New Salt Forms of Sabcomeline | Syremis Therapeutics, Ltd. (IL) | 2026-04-16 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| WO-2025067458-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND USE THEREOF | 苏州普乐康医药科技有限公司 | 2025-04-03 | — | — | WO | claimed |
| WO-2025067471-A1 | OPHTHALMIC COMPOSITION OF α-ADRENERGIC RECEPTOR AGONIST AND USE THEREOF | 苏州普乐康医药科技有限公司 | 2025-04-03 | — | — | WO | claimed |
| CN-119700756-A | Ophthalmic medicine composition and application thereof | 苏州普乐康医药科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119700908-A | A Chinese medicinal composition for treating gastric disease, and its preparation method and quality control method | 贵州中医药大学第二附属医院 | 2025-03-28 | — | — | CN | claimed |
| CN-119700989-A | Alpha-adrenergic receptor agonist ophthalmic composition and application thereof | 苏州普乐康医药科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20020127271-A1 | Formulation for the treatment and/or prophylaxis of dementia | SMITHKLINE BEECHAM P.L.C. | 2002-09-12 | — | — | US | claimed |
| EP-0759920-B1 | DERIVATIVES OF QUINUCLIDINE N-OXIDE AS MUSCARINIC RECEPTOR LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-14 | — | — | EP | claimed |
| EP-0786998-B1 | USE OF R-(Z)]-ALPHA-(METHOXYIMINO)-ALPHA-(1-AZABICYCLO 2.2.2] OCT-3-YL) ACETONITRILE TO REDUCE AMYLOID BETA A4 FORMATION IN ALZHEIMER'S DISEASE | SMITHKLINE BEECHAM PLC (GB) | 2002-03-27 | — | — | EP | claimed |
| WO-2001076571-A2 | USE OF SABCOMELINE IN THE TREATMENT OF ANXIETY | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-10-18 | — | — | WO | claimed |
| EP-1104301-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-06 | — | — | EP | claimed |
| WO-2000003717-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-27 | — | — | WO | claimed |
| EP-0786998-A1 | USE OF R-(Z)]-ALPHA-(METHOXYIMINO)-ALPHA-(1-AZABICYCLO 2.2.2] OCT-3-YL) ACETONITRILE TO REDUCE AMYLOID BETA A4 FORMATION IN ALZHEIMER'S DISEASE | SMITHKLINE BEECHAM PLC (GB) | 1997-08-06 | — | — | EP | claimed |
| EP-0759921-A1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1997-03-05 | — | — | EP | claimed |
| WO-1996012486-A1 | USE OF [R-(Z)]-ALPHA-(METHOXYIMINO)-ALPHA-(1-AZABICYCLO [2.2.2] OCT-3-YL) ACETONITRILE TO REDUCE AMYLOID BETA A4 FORMATION IN ALZHEIMER'S DISEASE | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-05-02 | — | — | WO | claimed |
| WO-1995031456-A1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1995-11-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116877-A1 | New Salt Forms of Sabcomeline | PSEN1, CHRM2, CHRM1 | CHRM2 2/4885CHRM4 5/4885CHRM1 3/4885 |
| US-20260102381-A1 | Muscarinic Agent Combinations | CHRM1, CHRM4, CHRM2 | CHRM2 3/4885CHRM4 2/4885CHRM1 1/4885 |
| US-20260116876-A1 | NEW SALT FORMS OF SABCOMELINE | CHRM1, CHRM2, PSEN1 | CHRM2 2/4885CHRM4 6/4885CHRM1 1/4885 |
| US-20260103460-A1 | New Salt Forms of Sabcomeline | APP, CHRM2, CHRM1 | CHRM2 2/4885CHRM4 6/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.